TheraRadar
← Back
Data updated: Jul 17, 2026

BIOPHARM

Generics
OncologyRespiratoryImmunology Execution: Needs Improvement

BIOPHARM is a generic drug manufacturer focused on Oncology, Respiratory, Immunology.

1997
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Dec 19, 2026 — Imlifidase
Dec 19, 2026 — Imlifidase
+1 more dates (Pro)

BIOPHARM's Key Drugs

BIOPHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BIOPHARM's Recent FDA Approvals

New NDA/BLA approvals for BIOPHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BIOPHARM's Therapeutic Areas

BIOPHARM's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 30%
0 drugs Phase 3: 1 Phase 2: 6 Phase 1: 11
Respiratory 21%
0 drugs Phase 2: 4 Phase 1: 11
Immunology 20%
1 drugs Phase 3: 1 Phase 2: 3 Phase 1: 2
Cardiovascular 17%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 5
Dermatology 12%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 3

BIOPHARM Pipeline Snapshot

BIOPHARM has 53 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 16 Phase 2 and 32 Phase 1.

5
Phase 3
16
Phase 2
32
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/3 completed
  • • Speed: N/A months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges